Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | TPMT | P51580 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31721787 | 0.87 | P4HB (0.44) | CA1CA2CA12CA7CA9 | |
| SCHEMBL30622253 | 0.86 | ALDH1A1 (0.48) | PKMHTTPOLBL3MBTL1ALDH1A1 | |
| SCHEMBL3496851 | 0.86 | TPMT (0.44) | CA1CA2TPMTCA12CA4 | |
| SCHEMBL24595665 | 0.86 | ALDH1A1 (0.48) | PKMHTTPOLBL3MBTL1ALDH1A1 | |
| SCHEMBL30622268 | 0.85 | NOTUM (0.50) | CA1CA2CA12CA7CA9 | |
| SCHEMBL25194022 | 0.85 | TSHR (0.44) | CA1CA2TPMTCA12CA4 | |
| SCHEMBL256771 | 0.85 | NOTUM (0.50) | CA1CA2CA12CA7CA9 | |
| SCHEMBL10035065 | 0.83 | ALDH1A1 (0.44) | CA1CA2TPMTCA12CA4 | |
| SCHEMBL28784707 | 0.83 | ALDH1A1 (0.44) | CA1CA2TPMTCA12CA4 | |
| SCHEMBL29133180 | 0.83 | GSK3B (0.49) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333398-A1 | MONOARYL AND HETARYL SUBSTITUTED INDAZOLES AND BENZIMIDAZOLES AS STING ANTAGONISTS AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INT (DE) | 2025-10-30 | — | — | US | disclosed |
| WO-2024101440-A1 | COMPOUND, ENDOTHELIN A RECEPTOR ANTAGONIST, ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION | 株式会社アークメディスン | 2024-05-16 | — | — | WO | disclosed |
| CN-117069724-A | Fused ring compounds, pharmaceutical compositions and uses | 上海赛默罗德生物科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-112513021-B | ROR gamma antagonist and application thereof in medicines | 广东东阳光药业有限公司 | 2023-06-27 | — | — | CN | disclosed |
| WO-2023085415-A1 | COMPOUND, ANGIOTENSIN-II TYPE 1 RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION | 株式会社アークメディスン | 2023-05-19 | — | — | WO | disclosed |
| WO-2023085415-A1 | COMPOUND, ANGIOTENSIN-II TYPE 1 RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION | 株式会社アークメディスン | 2023-05-19 | — | — | WO | disclosed |
| CN-112513021-A | ROR gamma antagonist and application thereof in medicine | 广东东阳光药业有限公司 | 2021-03-16 | — | — | CN | disclosed |
| EP-2414341-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-09-13 | — | — | EP | disclosed |
| EP-2414342-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-05-31 | — | — | EP | disclosed |
| EP-2193125-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-01-11 | — | — | EP | disclosed |
| WO-2010115751-A2 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010112461-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-10-07 | — | — | WO | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-2193125-A2 | OXADIAZOLE DERIVATIVES | Merck Serono S.A. (CH) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009043889-A2 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009043889-A2 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-04-09 | — | — | WO | disclosed |
| US-5200495-A | Rigid-rod benzobisazole polymer containing cyclic phosphate ester | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 1993-04-06 | — | — | US | disclosed |
| US-5175232-A | Rigid-rod benzobisazole copolymer containing cyclic phosphate ester | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 1992-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333398-A1 | MONOARYL AND HETARYL SUBSTITUTED INDAZOLES AND BENZIMIDAZOLES AS STING ANTAGONISTS AND THE USE THEREOF AS MEDICAMENT | STING1, MAVS, TBK1 | CA1 4884/4885CA2 3988/4885TPMT 496/4885 |
| US-20100240658-A1 | Oxadiazole Derivatives | OXA1L, RO60, NQO2 | CA1 2829/4885CA2 2987/4885TPMT 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.